



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/72, 1/21</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/05297</b> <b>(43) International Publication Date:</b> 4 February 1999 (04.02.99)
<b>(21) International Application Number:</b> PCT/GB98/02175 <b>(22) International Filing Date:</b> 21 July 1998 (21.07.98) <b>(30) Priority Data:</b> 9715660.8                      25 July 1997 (25.07.97)                      GB <b>(71) Applicant (for all designated States except US):</b> ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PIOLI, David [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). HOCKNEY, Robert, Craig [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). KARA, Buhpendra, Vallabh [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). BUNDELL, Kenneth, Robert [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). <b>(74) Agent:</b> PHILLIPS, Neil, Godfrey, Alasdair; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> T7 PROMOTER-BASED EXPRESSION SYSTEM <b>(57) Abstract</b> <p>An improved T7 based promoter-driven protein expression system comprising an operator sequence downstream of the T7 promoter sequence, and having a further operator sequence upstream of the T7 promoter sequence.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## T7 PROMOTER-BASED EXPRESSION SYSTEM

The invention relates to expression systems for the recombinant synthesis of polypeptides, in particular to T7 promoter-driven protein expression systems. The invention also relates to  
5 expression vectors for use in such systems.

A large number of mammalian, yeast and bacterial host expression systems are known (Methods in Enzymology (1990), 185, Editor: D.V. Goeddel). Of particular interest are those which use T7 RNA polymerase. The ability of T7 RNA polymerase and equivalent RNA polymerases from T7-like phages to transcribe selectively any DNA that is linked to an  
10 appropriate promoter can serve as the basis for a very specific and efficient production of desired RNAs both *in vitro* and inside a cell.

US-A-4952496 (Studier) discloses a process whereby T7 RNA polymerase can be expressed and used to direct the production of specific proteins, all within a host *E. coli* cell. Specific proteins of interest include antigens for vaccines, hormones, enzymes, or other proteins  
15 of medical or commercial value. Potentially, the selectivity and efficiency of the phage RNA polymerase could make such production very efficient. Furthermore, the unique properties of these phage RNA polymerases may make it possible for them to direct efficient expression of genes that are expressed only inefficiently or not at all by other RNA polymerases. These phage polymerases have the further advantage that it is possible to selectively inhibit the host cell RNA  
20 polymerase so that all transcription in the cell will be due to the phage RNA polymerase.

An expression system based on the above is now commercially available. This is the pET system obtainable from Novagen Inc. 597 Science Drive, Madison, WI 53711. This system is suitable for the cloning and expression of recombinant proteins in *E. coli*. See also Moffat et al, J.Mol. Biol., 1986, 189, 113-130; Rosenberg et al, Gene, 56, 125-135; and Studier et al, Meth.  
25 Enzymol. 1990, 185, 60-89.

However, despite the provision of the pET system, there remains the need for further, improved T7 promoter-driven expression systems.

We have now devised such a system which provides improved control of expression and improved levels of protein expression, when compared to available T7-based expression systems.  
30 We provide a T7 promoter-driven expression system wherein basal expression in the absence of inducer is reduced to a level which permits the cloning and expression of toxic gene products not possible with currently available T7 based expression systems whilst not influencing induced productivity. Moreover, our present invention also allows control of production of heterologous proteins in an inducer concentration-dependent manner over a wide range of expression levels so

that an optimum level of expression can be identified. This level of control over expression and production of heterologous protein is not possible with currently available T7 based expression systems.

Therefore in a first aspect of the invention we provide a T7 promoter-driven protein  
5 expression system comprising an operator sequence downstream of the T7 promoter sequence, and having a further operator sequence upstream of the T7 promoter sequence.

We have found that the further operator is preferably a native lac operator (lacO) sequence. Or a perfect palindrome operator (ppop) sequence. More preferably the native (lac) operator sequence downstream of the T7 promoter sequence is replaced by a ppop sequence, so as  
10 to provide a tandem ppop operator.

The T7 promoter driven expression system is conveniently constructed as follows: The target gene of interest is cloned in a plasmid under control of bacteriophage transcription and translation signals. The target gene is initially cloned using a host such as *E.coli* DH5 $\alpha$ , HB101 that does not contain the T7 RNA polymerase gene. Once established, plasmids are transferred  
15 into expression hosts containing a chromosomal copy of the T7 RNA polymerase gene under for example lac UV5 control. Other convenient promoters include lac, trp, tac, trc, and bacteriophage  $\lambda$  promoters such as pL and pR. Expression is then induced by the addition of an inducer such as IPTG (isopropyl- $\beta$ -D-1-thiogalactopyranoside), lactose or melibiose. Other inducers may be used and are described more fully elsewhere. See The Operon, eds Miller and  
20 Reznikoff (1978). Inducers may be used individually or in combination.

The plasmid preferably includes one or more of the following: a selectable antibiotic resistance sequence, a cer stability element, and a multiple cloning site. The construction of appropriate plasmids will be apparent to the scientist of ordinary skill. Examples of preferred plasmids comprising one or more of the above features are illustrated by the pZT7#3-series of  
25 plasmids in the accompanying Figures. These were constructed starting from a vector pZEN0042 disclosed (as pICI0042) in our European Patent Application No. 0 502 637 (ICI). The 3-series plasmids of this invention include pZT7#3.0, pZT7#3.1, pZT7#3.2 and pZT7#3.3. A particularly preferred plasmid of this invention is the pZT7#3.3 plasmid.

The chromosomal copy of the T7 RNA polymerase gene, for example under lac UV5  
30 control, is preferably introduced into the host cells via the  $\lambda$  bacteriophage construct,  $\lambda$ DE3, obtainable from Novagen. The T7 RNA polymerase expression cassette may also be delivered to the cell by infection with a specialised bacteriophage  $\lambda$  transducing phage that carries the gene (CE6, see US-A-4952496).

Compatible plasmids such as pLysS and pLysE (also available from Novagen) may also be introduced into the expression host. These plasmids encode T7 lysozyme, which is a natural and selective inhibitor of T7 RNA polymerase, and thus reduces its ability to transcribe target genes in uninduced cells. pLysS hosts produce low amounts of T7 lysozyme, while pLysE hosts  
5 produce much more enzyme and therefore provide more stringent control.

Any convenient compatible prokaryotic or eukaryotic host cell may be used. The most commonly used prokaryotic hosts are strains of *E.coli*, although other prokaryotic hosts such as *Salmonella typhimurium*, *Serratia marsescens*, *Bacillus subtilis* or *Pseudomonas aeruginosa* may also be used. Mammalian (e.g. Chinese hamster ovary cells) or other eukaryotic host cells such as  
10 those of yeast (e.g. *Saccharomyces cerevisiae*, *Pichia pastoris*, *Hansenula polymorpha*, *Schizosaccharomyces pombe* or *Kluyveromyces lactis*), filamentous fungi, plant, insect, amphibian or ovarian species may also be useful. A particular host organism is a bacterium, preferably *E. coli* (e.g. K12 or B strains).

Any convenient growth medium may be used depending on the host organism used. For  
15 *E.coli*, practice of this invention includes, but is not limited to complex growth media such as L-broth or minimal growth media such as M9 (described hereinafter).

The invention will now be illustrated but not limited by reference to the following detailed description Examples, Tables and Figures wherein:

Table 1 gives details of plasmids expressing h-TNF $\alpha$  used in the Examples.  
20 Tables 2-4 gives details of vectors used in the Examples and their relative performance.  
Table 5 gives details of the composition of M9 minimal growth medium.  
Table 6 gives details of h-TNF $\alpha$  expression in various growth media.  
Table 7 gives details of host/transformation efficiencies for vectors used in the Examples.  
Table 8 gives details of DNase 1 productivity in conjunction with the

25 pZT7#3.3:DNase 1 vector.

Tables 9-11 give details of accumulation levels for LAR d1 (aa1275-1623), ZAP70 (4-260) 6HIS and MCP-1 {9-76} used in the Examples.

Table 12 shows the sequences of oligonucleotides used in the construction of pZT7#3.3 and intermediate vectors.

30 Table 13 shows the nucleic acid sequence of hTNF $\alpha$ .

Table 14 shows the ZAP70 (4-260) 6HIS nucleic acid sequence.

Table 15 shows the LAR d1 (aa1275-1623) nucleic acid sequence.

Table 16 shows the bovine pancreatic DNase 1 nucleic acid sequence.

Table 17 shows the human carboxypeptidase B (mutant D253>K) 6His cmc sequence.

Table 18 shows various *E. coli* expression strains.

Table 19 shows the human monocyte chemotactic protein MCP-1 {9-76} sequence.

Table 20 shows the A5B7 F(ab')<sub>2</sub> nucleic acid sequence.

5

Figure 1 shows the pZEN0042 plasmid.

Figure 2 shows the construction of pZEN0042#a from pZEN0042.

Figure 3 shows the pZEN0042#b plasmid.

Figure 4 shows the pZEN0042#c plasmid.

10 Figure 5 shows the pZEN0042#d plasmid.

Figure 6 shows the pZEN0042#e plasmid.

Figure 7 shows the pZT7#2.0 plasmid.

Figure 8 shows the pZT7#2.1 plasmid.

Figure 9 shows the pZT7#3.0 plasmid of the invention.

15 Figure 10 shows the pZT7#3.2 plasmid of the invention.

Figure 11 shows the pZT7#3.1 plasmid of the invention.

Figure 12 shows the pZT7#3.3 plasmid of the invention.

Figure 13 shows the peak specific productivity attained at various IPTG concentrations.

20 Figure 14 shows the maximum hTNF $\alpha$  accumulation level attained at various IPTG concentrations..

Figure 15 shows the accumulation of biologically active CPB[D253K]-6His-cmyc (as  $\mu$ g active material /L of culture) attained at various IPTG concentrations.

25 Figure 16 shows the accumulation in the periplasm of *E.coli* of biologically active A5B7(Fab')<sub>2</sub>/A5B7(Fab') (as mg active material/L of culture) attained at various IPTG concentrations.

Specific description:

### **1. Generation of pZT7 series vectors**

30 The starting vector for generation of pZT7#3.3 was pZEN0042, described fully in our European Patent Application, Publication No. 0502637. Briefly, this vector contains the tetA/tetR inducible tetracycline resistance sequence from plasmid RP4 and the cer stability sequence from plasmid pKS492 in a pAT153 derived background (Figure 1).

### **1(i) Cloning of lac I**

The sequence of lac I including the lac repressor coding sequence and lac I promoter was generated by polymerase chain reaction using genomic DNA prepared from *E.coli* strain MSD 101 (W3110). Nsi I restriction endonuclease sites were generated at both ends of the sequence by incorporation into the PCR primers #1 a

nd #2 (Table 12). The PCR product obtained was digested with Nsi I and cloned into pZEN0042 at the Pst I site (Pst I and Nsi I have compatible cohesive ends resulting in both sites being destroyed). Both orientations of lac I were obtained. A clone with a correct sequence lac I in the anti-clockwise orientation was identified (=pZEN0042#a) (Figure 2).

### **1(ii) Cloning of polylinker**

A new multiple cloning site was generated in pZEN0042#a to allow subsequent cloning of the T7 expression cassette. This was achieved by digesting pZEN0042#a with EcoR I and BamH I and ligating with annealed, synthetic oligomers #3 and #4 (Table 12).

The polylinker of the resulting vector, pZEN0042#b, had the following restriction sites: EcoRI - Nde I - Kpn I - Sca I - Spe I - BamH I - Xho I - Pst I - Hind III - Bgl II.

pZEN0042#b is shown in Figure 3.

## **2. Cloning of T7 expression elements**

### **2(i) T7 terminator**

The T7 terminator sequence from T7 gene 10 was cloned as annealed synthetic oligomers #5 and #6 (Table 12) between the Hind III and Bgl II sites of pZEN0042#b to generate pZEN0042#c (Figure 4).

### **2(ii) tRNA<sup>arg5</sup>**

The tRNA<sup>arg5</sup> transcriptional reporter sequence (Lopez, *et al*, (1994), NAR 22, 1186-1193, and NAR 22, 2434) was cloned as annealed synthetic oligomers #7 and #8 (Table 12) between the Xho I and Pst I sites in pZEN0042#c to generate pZEN0042#d (Figure 5).

### **2(iii) Upstream terminator**

As the tetA sequence has no recognisable terminator, a T4 terminator sequence was cloned upstream of the EcoR I site to reduce potential transcriptional readthrough from tetA (or any other unidentified promoter sequence) into the T7 expression cassette (to be cloned

downstream of the EcoR I site). Annealed synthetic oligomers #9 and #10 (Table 12) containing the T4 terminator sequence and an additional Nco I site were cloned between the Stu I and EcoR I sites in pZEN0042#d to generate pZEN0042#e (Figure 6).

#### 5 2(iv) T7 lac promoter

The T7 promoter and lac operator sequence was cloned as annealed synthetic oligonucleotides #11 and #12 (Table 12) between the EcoR I and Nde I sites of pZEN0042#e to generate pZT7#2.0 (Figure 7). This configuration of T7 promoter and lac operator is equivalent to pET11a.

10

#### 2(v) T7 promoter with perfect palindrome operator

The T7 gene 10 promoter incorporating a perfect palindrome lac operator sequence (Simons *et al* (1984), PNAS 81,1624-1628) was cloned as annealed synthetic oligomers #13 and #14 (Table 12) between the EcoR I and Nde I sites of pZEN0042#e to generate pZT7#2.1 (Figure 15 8).

#### 2(vi) Upstream lac operator

A second native lac operator sequence was cloned 94 base pairs upstream of the lac operator sequence in pT7#2.0 as annealed synthetic oligomers #15 and #16 (Table 12) between the Nco I and EcoR I sites of pZT7#2.0 to generate pZT7#3.0 (Figure 9).

20

The same lac operator sequence was cloned similarly into pZT7#2.1 to generate pZT7#3.2 (figure 10).

#### 2(vii) Upstream perfect palindrome lac operator

A perfect palindrome operator sequence was positioned 94 bp upstream of the lac operator sequence of pZT7#2.0 by cloning of annealed synthetic oligomers #17 and #18 (Table 12) between the Nco I and EcoR I sites of pZT7#2.0 to generate pZT7#3.1 (Figure 11).

25

The same perfect palindrome operator sequence was cloned similarly into pZT7#2.1 to generate pZT7#3.3 (Figure 12).

30

### 3. Generation of test constructs

#### pET11a

T7 expression vector pET11a was obtained from Novagen Inc and used as a control for the testing of the pZT7 vectors



**3(i) hTNF $\alpha$** 

An Nde I - BamH I DNA fragment containing the coding sequence of human TNF $\alpha$  was cloned between the Nde I and BamH I sites in vectors pZT7#2.0, pZT7#2.1, pZT7#3.0, pZT7#3.1, pZT7#3.2, pZT7#3.3 and pET11a. The sequence cloned is shown in Table 13

5

**3(ii) ZAP70 (4-260) 6HIS**

A DNA fragment encoding amino acids 4-260 of human protein tyrosine kinase ZAP70 with a C-terminal hexahistidine tag sequence was subcloned as a Nde I - Bgl II fragment between the Nde I and BamH I cloning sites of pET11a and pZT7#3.3. The sequence cloned is shown in Table 14.

10

**3(iii) LAR d1 (aa1275-1623)**

The leukocyte antigen related protein tyrosine phosphatase domain 1 (aa1275-1613) was subcloned as a Nde I - Bgl II fragment into pET 11a and pZT7#3.3 (Nde I - BamH I). The sequence cloned is shown in Table 15.

15

**3(iv) human carboxypeptidase B (mutant D253>K) 6His cmvc**

The coding sequence of a mutant human carboxypeptidase (D253>K) with a C-terminal hexahistidine cmvc tag sequence was placed downstream of the *Erwinia carotovora pel B* secretory leader sequence and cloned into pZT7#3.3 and pET11a. The sequence cloned is shown in Table 17

20

**3(v) Bovine pancreatic DNase 1**

The coding sequence of bovine pancreatic DNase I was cloned as an Nde I - Bgl II fragment between the Nde I and BamH I sites in pZT7#3.3. The sequence cloned is shown in Table 16.

25

This sequence could not be cloned without mutation in pET11a.

However, a bovine pancreatic DNase1 sequence had previously been cloned into pET11 (not pET11a) (Doherty *et al* (1993) Gene, 136, pp337-340). In this construct the 5' untranslated region including the ribosome binding site is derived from the native bovine pancreatic DNase 1 sequence rather than from T7 gene 10 as in pT7#3.3. This construct, pAD10, was used as a control for pT7#3.3.

30

**3(vi) human monocyte chemotactic protein MCP-1 {aa9-76}**

The coding sequence of human monocyte chemotactic protein (aa9-76) was cloned between the Nde I and BamH I sites of pZT7#3.3 and pET11a. The sequence cloned is shown in Table 19.

5

**3(vii) A5B7 F(ab')<sub>2</sub>**

The coding sequence of A5B7 F(ab')<sub>2</sub> was placed downstream of the *Erwinia carotovora pel B* secretory leader sequence and cloned between the Nde I and BamH I sites of pZT7#3.3 and pET11a. The sequence cloned is shown in Table 20.

10

**4. Generation of host strains for T7 expression**

A λDE3 lysogenisation kit was obtained from Novagen Inc and used according to the instructions to generate T7 expression hosts from the *E.coli* strains listed in Table 18. Plasmids pLysS and pLysE and *E.coli* expression hosts BL21 and BL21(DE3) were obtained from Novagen Inc.

15

**Example 1**

*E.coli* strains BL21(DE3), BL21(DE3) pLysS, BL21(DE3) pLysE were transformed separately with plasmids (described below, Table 1) expressing human TNFα. The resultant recombinant strains were purified and maintained in glycerol stocks at -80°C. Host strains BL21(DE3), BL21(DE3) pLysS and BL21(DE3)pLysE are used extensively in the art and are freely available to the public, for example, from Novagen Inc (Madison, USA). The genotype of BL21(DE3) is F<sup>-</sup>, ompT, hsdS<sub>B</sub>(r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>), gal, dcm, (DE3).

20

25 **Table 1**

Host	Plasmid	Description	Recombinant Designation No
BL21(DE3)	pZen1798	pET11a:TNFα	BL21(DE3) pZen1798
BL21(DE3)	pZen1830	pZT7#2.0:TNFα	BL21(DE3) pZen1830
BL21(DE3)	pZen1832	pZT7#2.1:TNFα	BL21(DE3) pZen1832
BL21(DE3)	pZen1835	pZT7#3.0:TNFα	BL21(DE3) pZen1835
BL21(DE3)	pZen1836	pZT7#3.1:TNFα	BL21(DE3) pZen1836

-9-

BL21(DE3)	pZen1826	pZT7#3.2:TNF $\alpha$	BL21(DE3) pZen1826
BL21(DE3)	pZen1827	pZT7#3.3:TNF $\alpha$	BL21(DE3) pZen1827
BL21(DE3) pLysS	pZen1798	pET11a:TNF $\alpha$	BL21(DE3) pLysS/pZen1798
BL21(DE3) pLysE	pZen1798	pET11a:TNF $\alpha$	BL21(DE3) pLysE/pZen1798
BL21(DE3) pLysS	pZen1830	pZT7#2.0:TNF $\alpha$	BL21(DE3) pLysS/pZen1830
BL21(DE3) pLysE	pZen1830	pZT7#2.0:TNF $\alpha$	BL21(DE3) pLysE/pZen1830

An aliquot of each recombinant strain was removed from stock and streaked onto L-agar plates (supplemented with ampicillin (50 $\mu$ g/ml) or tetracycline (10 $\mu$ g/ml) and/or chloramphenicol (1 $\mu$ g/ml) to maintain selection as appropriate) and incubated at 37°C for 16 hours. An aliquot of each culture was then resuspended in 10ml of sterile PBS (phosphate buffered saline solution; 8g/L sodium chloride, 0.2g/L potassium chloride, 0.2g/L potassium di-hydrogen orthophosphate, 1.15g/L magnesium chloride) and used to inoculate to OD<sub>550</sub> = 0.1 each of two 250ml Erlenmeyer flasks containing 75ml of L-broth (10g/L tryptone (Difco), 5g/L yeast extract (Difco), 5g/L sodium chloride; pH 7.2) supplemented with tetracycline (10 $\mu$ g/ml) or ampicillin (50 $\mu$ g/ml) and/or chloramphenicol (1 $\mu$ g/ml) as appropriate. The flasks were then incubated at 37°C on a reciprocating shaker. Growth was monitored until OD<sub>550</sub> = 0.4-0.5. At this point cultures were induced by adding the inducer, IPTG (isopropyl- $\beta$ -D-1-thiogalactopyranoside), to a final concentration of 1mM to one flask from each set (of two) for each recombinant strain. The second flask was not induced. Both flasks for each recombinant strain were incubated under the conditions described above for a further 24h. The accumulation level of hTNF $\alpha$  in the induced cultures was determined by laser densitometry scanning of Coomassie blue stained gels following SDS-PAGE of the sampled bacteria. The basal accumulation level of hTNF $\alpha$  in the un-induced cultures was determined by Western blot analysis (using an anti-hTNF $\alpha$  antibody) following SDS-PAGE of the sampled bacteria. The accumulation level in terms of molecules of hTNF $\alpha$  per cell was then determined by laser densitometry scanning of the blots (prepared using known standards together with the "unknowns") as is well established in the art. The results are summarised below (Table 2).

**Table 2**

VECTOR	hTNF $\alpha$ Accumulation level: Basal and Induced			
	Operator <sup>(1)</sup>	Basal % TMP <sup>(2)</sup>	Basal mol/cell <sup>(3)</sup>	Induced % TMP <sup>(2)</sup>
pET11a	single native lacO	3.06	98000	30
pZT7#2.0	single native lacO	2.66	85000	33
pZT7#3.0	dual native lacO	0.14	4500	31
pZT7#2.1	single ppop lacO	1.22	39000	33
pZT7#3.1	dual ppop/native lacO	0.59	19000	37
pZT7#3.2	dual native/ppop lacO	0.08	2400	39
pZT7#3.3	dual ppop lacO	0.016	500	44
pET11a/pLysS	single native lacO	0.045	1400	2.2
pET11a/pLysE	single native lacO	0.025	800	0.21
pZT7#2.0/pLysS	single native lacO	0.02	600	1.2
pZT7#2.0/pLysE	single native lacO	nd <sup>(4)</sup>	nd <sup>(4)</sup>	0.15

(1): described more fully in the text

(2): TMP = Total Microbial Protein

5 (3): mol/cell = molecules of hTNF $\alpha$  per cell; detection limit: 250 molecules/cell

(4): nd = not detected (Western blot)

The data presented above clearly shows that the level of basal expression of a heterologous protein is still high using the current established art (single native lac operator:

vectors pET11a/ pZT7#2.0). Basal expression can be reduced with pET11a/pZT7#2.0 expression systems by use of host strains co-transformed with plasmids expressing T7 lysozyme (pLysS/pLysE). However, the induced productivity is severely compromised.

Surprisingly, the dual native lac operator sequence works with a T7 promoter driven system reducing basal expression levels significantly whilst not influencing induced productivity.

More surprisingly, the dual perfect palindrome operator performs the best in reducing basal expression levels yet further without compromising induced productivity. This is totally unexpected given that the use of a single perfect palindrome operator with a T7 promoter driven system does not yield a significant improvement in reducing basal expression. Other combinations of the native and ppop lac operators may also be used e.g. pZT7#3.2 and pZT7#3.1.

### **Example 2**

*E.coli* strains MSD 623(DE3), MSD 624(DE3), MSD 68(DE3), MSD 101(DE3) and MSD 522(DE3) - see Table 18, were transformed separately with plasmids pET11a:TNF, pZT7#2.0:TNF, pZT7#2.1:TNF, pZT7#3.0:TNF, pZT7#3.1:TNF, pZT7#3.2:TNF and pZT7#3.3:TNF expressing human TNF $\alpha$  (described previously (Table 1)). The resultant recombinant strains were purified and maintained in glycerol stocks at -80°C. The level of basal and induced expression/accumulation of hTNF $\alpha$  was determined exactly as described in Example 1. The basal (un-induced) and IPTG induced level of hTNF $\alpha$  expression/ accumulation are summarised below in Table 3 and 4 respectively. The data obtained using host strain BL21(DE3), described in Example 1, is included for reference.

**Table 3**

VECTOR	Host Strain/Basal hTNF $\alpha$ accumulation level: molecules per cell*					
	BL21 (DE3)	MSD623 (DE3)	MSD624 (DE3)	MSD68 (DE3)	MSD101 (DE3)	MSD522 (DE3)
pET11a	98000	7600	4200	2300	4300	6500
pZT7#2.0	85000	7000	2800	3000	5300	3000
pZT7#2.1	39000	5000	2000	1300	3300	2500
pZT7#3.0	4500	650	300	250	400	700
pZT7#3.1	19000	1100	400	300	900	800

<b>pZT7#3.2</b>	2400	1000	300	250	400	350
<b>pZT7#3.3</b>	500	800	400	250	300	800

\*Detection limit: 250 molecules/cell.

**Table 4**

<b>VECTOR</b>	<b>Host Strain/hTNF<math>\alpha</math> accumulation after induction (% TMP)*</b>					
	<b>BL21 (DE3)</b>	<b>MSD623 (DE3)</b>	<b>MSD624 (DE3)</b>	<b>MSD68 (DE3)</b>	<b>MSD101 (DE3)</b>	<b>MSD522 (DE3)</b>
<b>pET11a</b>	30	33	29	37	32	34
<b>pZT7#2.0</b>	33	29	33	33	38	16
<b>pZT7#2.1</b>	33	36	46	47	44	47
<b>pZT7#3.0</b>	31	28	39	36	34	36
<b>pZT7#3.1</b>	37	27	38	37	38	36
<b>pZT7#3.2</b>	39	32	48	47	43	42
<b>pZT7#3.3</b>	44	38	48	47	45	39

5

(\*): TMP = Total Microbial Protein

The data presented above show that pZT7#3.0, pZT7#3.1, pZT7#3.2 and pZT7#3.3 decrease the level of basal expression (compared to pET11a/pZT7#2.0) with all host strains tested without adversely influencing the induced productivity. pZT7#3.3 is consistently superior for all host  
10 strains tested.

### **Example 3**

Aliquots of *E.coli* strains MSD 101(DE3) pZen1798 (pET11a:TNF) and MSD 101(DE3) pZen1827 (pZT7#3.3:TNF) from glycerol stocks at -80°C were streaked onto plates of L-agar  
15 (supplemented with ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate to maintain selection) and incubated at 37°C for 16 hours. An aliquot of each culture was then resuspended in 10ml of sterile PBS and used to inoculate, to OD<sub>550</sub> = 0.1, 250ml Erlenmeyer flasks containing 75ml of :

1. L-broth (no glucose),
2. L-broth + 1g/L glucose,
3. M9 minimal medium with 2g/L glucose, and
4. M9 minimal medium with 4g/L glycerol.

5

All the growth media used above were supplemented with ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate. The composition of M9 minimal medium is given in Table 5 below. The composition of L-broth medium has been described previously.

10 **Table 5: Composition of M9 minimal medium**

Component	g/L deionised water*
di-sodium hydrogen orthophosphate	6.0
potassium di-hydrogen orthophosphate	3.0
ammonium chloride	1.0
sodium chloride	0.5
magnesium sulphate hepta-hydrate	1mM
calcium chloride di-hydrate	0.1mM
thiamine	4µg/ml
casein hydrolysate (Oxoid L41)	0.2

(\* Final pH adjusted to pH 7.0)

The flasks were then incubated at 37°C on a reciprocating shaker for 24 hours. The basal accumulation level of hTNFα in the un-induced cultures (summarised below in Table 6) was  
15 determined exactly as previously described.

**Table 6**

VECTOR	Growth medium/Basal hTNFα accumulation level (molecules per cell)*			
	L-broth no glucose	L-broth 1g/L glucose	M9 minimal 2g/L glucose	M9 minimal 4g/L glycerol
pET11a	58000	24000	5100	64000
pZT7#3.3	320	250	<250	<250

\*Detection limit: 250 molecules/cell

This example demonstrates the wide utility of vector pZT7#3.3. Whereas pET11a shows growth medium dependant repression of expression, vector pZT7#3.3 in sharp contrast shows tight repression in both L-broth and M9 minimal growth media. This was surprising and totally unexpected. L-broth and M9 minimal growth media represent the two basic forms of microbial growth media: complex (L-broth) and minimal salts (M9).

#### Example 4

10

The utility of vector pZT7#3.3 for the cloning and overproduction of toxic proteins is exemplified in this example using recombinant bovine pancreatic deoxyribonuclease (DNase 1). Host strains BL21 (non-expressing host background) and BL21(DE3) (expressing background) were transformed as follows. Competant cells prepared using the  $\text{CaCl}_2$  method (Sambrook, Fritsch and Maniatis, 1989, "Molecular Cloning", 2nd Edition, Cold Spring Harbour Press, New York) were transformed with a range of plasmid DNA concentrations using the "heat shock" method (Sambrook, Fritsch and Maniatis, 1989, "Molecular Cloning", 2nd Edition, Cold Spring Harbour Press, New York) with pZen2006 (pAD10, the pET11 derivative expressing DNase 1 described previously), pZen1980 (pZT7#3.3:DNase 1) and pZen1827 (pZT7#3.3:TNF) expressing hTNF $\alpha$  (used as a control: relatively non-toxic gene product). The transformation efficiency of each host-plasmid combination was determined as is well described in the art. The results are summarised below in Table 7.

Table 7

25

VECTOR	Host/Transformation Efficiency: transformants/ $\mu\text{g}$ plasmid DNA*	
	BL21: non expressing background	BL21(DE3): expressing background
pET11a	no clones	
pAD10 Dnase 1	$2.2 \times 10^5$ (+/- $2.2 \times 10^4$ )	120 (+/- 170)
pZT7#3.3	$2.7 \times 10^5$	$3.7 \times 10^5$



<b>Dnase 1</b>	(+/- $3.6 \times 10^4$ )	(+/- $1.4 \times 10^4$ )
<b>pZT7#3.3</b>	$2.5 \times 10^5$	$3.5 \times 10^5$
<b>hTNF<math>\alpha</math></b>	(+/- $3.7 \times 10^4$ )	(+/- $6.4 \times 10^4$ )

\*Data from three separate experiments (n=3)

The above data clearly exemplifies the tight control of basal expression that is achieved using pZT7#3.3. The results show that pZT7#3.3:DNase 1 is sufficiently repressed to support transfer  
5 into a cell expressing T7 RNA polymerase (BL21(DE3)) without a deleterious effect on cell viability. Transformation efficiencies achieved are equivalent to those obtained with transformation into BL21 (no T7 RNA polymerase) or to those with a relatively non-toxic gene product pZT7#3.3:hTNF $\alpha$ . If expression of DNase 1 had been leaky the cells would have been killed. This is in contrast to the results obtained with pET11a and pAD10. It will be clearly  
10 evident to those experienced in the art how pZT7#3.3 may be used to circumvent the problem of the deleterious effect that a heterologous protein can have on growth and productivity of recombinant cells.

The expression/accumulation of DNase 1 using BL21(DE3) pZen1980 (pZT7#3.3:DNase 1) was  
15 determined by taking single colony of a BL21(DE3) pZen1980 transformant from the experiment described above and using this to inoculate a single Erlenmeyer flask containing 75ml of L-broth (1g/L glucose, 10 $\mu$ g/ml tetracycline). The flask was incubated at 37°C on a reciprocating shaker for 16 hours. This culture was then used to inoculate fresh L-broth (1g/L glucose, 10 $\mu$ g/ml tetracycline) to OD<sub>550</sub> = 0.1. The flask was then incubated at 37°C on a reciprocating shaker until  
20 the growth reached OD<sub>550</sub> = 0.5. The culture was then induced by adding IPTG (0.5mM final) and the incubation continued, under the conditions described, for a further 4 hours. The cells were harvested and the cell pellet stored at -20°C. The cell pellet was thawed and resuspended (10% w/v (wet weight)) in lysis buffer (10mM Tris; pH 7.6, 2mM calcium chloride, 100 $\mu$ M benzamidine and 100 $\mu$ M phenylmethylsulfonyl flouride (PMSF)). The cell suspension was then  
25 sonicated (20-30 second bursts followed by a period on ice) until examination of the suspension by light microscopy indicated >95% cell breakage. The cell debris was removed by centrifugation (4°C, 25000 x g, 20 minutes) and DNase 1 activity in the supernatant determined by adding 100 $\mu$ l of the cleared supernatant to 1ml of Kunitz assay buffer (10mM Tris; pH 8.0, 0.1mM calcium chloride, 1mM magnesium chloride and 50 $\mu$ g calf thymus DNA). One "Kunitz Unit" is that

amount of DNase 1 that causes an increase in the  $A_{260\text{nm}}$  of 0.001/min. The results are summarised below in Table 8.

**Table 8**

5

Host/Vector	Growth $OD_{550}$ at harvest	Dnase 1 Activity: Kunitz Units per litre of culture
BL21(DE3) pZen1980 (pZT7#3.3:DNase 1)	4.0	$2 \times 10^5$

Doherty *et al* (Gene, 1993, 136, pp337-340) found that on transformation of BL21(DE3) with pAD10, no viable bacterial colonies were obtained. This is essentially similar (given the standard deviation in the data) to our observations (described above in Table 7). Even with BL21(DE3) pLysS, Doherty *et al* found that transformants had poor viability when transferred to liquid media. In sharp contrast BL21(DE3) transformed with pZen1980 (pZT7#3.3:DNase 1) achieves high transformation efficiencies which are equivalent to those achieved using a non-expressing host background and moreover BL21(DE3) pZen1980 transformants demonstrate high viability in liquid culture and retain the ability to express biologically active DNase 1 even after sub-culture.

15

#### **Example 5**

Aliquots of *E.coli* strains MSD 101(DE3) pZen1798 (pET11a:TNF) and MSD 101(DE3) pZen1827 (pZT7#3.3:TNF) from glycerol stocks at  $-80^{\circ}\text{C}$  were streaked onto plates of L-agar (supplemented with ampicillin (50 $\mu\text{g/ml}$ ) or tetracycline (10 $\mu\text{g/ml}$ ) as appropriate to maintain selection) and incubated at  $37^{\circ}\text{C}$  for 16 hours. An aliquot of each culture was used to inoculate each of two 250ml Erlenmeyer flasks containing 75ml of M9 minimal medium (2g/L glucose supplemented with ampicillin (50 $\mu\text{g/ml}$ ) or tetracycline (10 $\mu\text{g/ml}$ ) as appropriate). The cultures were incubated at  $37^{\circ}\text{C}$  for 16 hours on a reciprocal shaker and used to inoculate separately to  $OD_{550} = 0.1$  each of five 2L Erlenmeyer flasks containing 600ml of M9 minimal medium (2g/L glucose supplemented with ampicillin (50 $\mu\text{g/ml}$ ) or tetracycline (10 $\mu\text{g/ml}$ ) as appropriate). The composition of M9 minimal medium is given in Table 5. The flasks were incubated at  $37^{\circ}\text{C}$  on a reciprocal shaker and the growth monitored periodically by measuring the  $OD_{550}$  of the culture. When the growth reached  $OD_{550} = 0.5$  the cultures were induced by adding the inducer IPTG to

25

each flask (0.25mM, 0.075mM, 0.05mM, 0.025mM and 0.01mM (final)). The incubation was continued under the conditions described for a further 10 hours during which samples were taken for measurement of growth, accumulation of hTNF $\alpha$  and total microbial protein within the bacterial cells. The accumulation level of hTNF $\alpha$  was measured by scanning Coomassie blue stained SDS-PAGE gels of whole cell lysates of the sampled bacteria as is well known in the art. The level of total microbial protein was determined using the BCA Protein Assay Reagent (Pierce, Rockford, IL) used in accordance with the manufacturers instructions. The accumulation level of biomass was determined by calculating the dry weight of the biomass from the OD<sub>550</sub> measurements as is well established in the art. The specific productivity ( $Q_p$ ) of hTNF $\alpha$  (mg hTNF $\alpha$  produced per gram dry weight cells per hour) was calculated for each sample point during the induction period using protocols well established in the art. The  $Q_{p(max)}$  (peak specific productivity) and maximum hTNF $\alpha$  accumulation level (% total microbial protein) attained with each IPTG concentration used for induction) are summarised in Figures 13 and 14 respectively (\*TMP = Total microbial protein).

15

These results show that adding IPTG to the medium at increasing concentrations induces expression in a dose-dependant manner with pZT7#3.3. However, with pET11a expression is induced to near maximum levels even at very low concentrations of inducer. It will be evident how this surprising and unexpected property of pZT7#3.3 allows those skilled in the art to control production of heterologous proteins over a wide range of expression levels so that an optimum level of expression can be identified. This is exemplified by Examples 9 and 10.

### **Example 6**

*E.coli* strains BL21(DE3) and BL21(DE3) pLysS were transformed separately with plasmid pZen1911 (pET11a:LARd1(1275-1613) expressing LARd1(1275-1613). *E.coli* strains MSD460(DE3) and MSD460(DE3) pLysS were transformed separately with plasmid pZen1914 (pET11a:ZAP70(4-260)-6His) expressing ZAP70(4-260)-6His. The resultant recombinant strains were purified and maintained in glycerol stocks at -80°C. An aliquot of each culture was removed from stock and streaked separately on to L-agar plates (supplemented with ampicillin (50 $\mu$ g/ml) or ampicillin (50 $\mu$ g/ml) and chloramphenicol (1 $\mu$ g/ml) as appropriate to maintain selection) to separate single colonies after growth for 16 hours at 37°C. A single colony of each culture was then inoculated separately into a 250ml Erlenmeyer flasks containing 75ml of L-broth (+ 1g/L glucose and ampicillin (50 $\mu$ g/ml) or ampicillin (50 $\mu$ g/ml) and chloramphenicol (1 $\mu$ g/ml)) as

appropriate). The flasks were incubated at 37°C on a reciprocating shaker for 16 hours. Each of these seeder cultures was then used to inoculate separately 250ml Erlenmeyer flasks containing 75ml L-broth (1g/L glucose and ampicillin (50µg/ml) or ampicillin (50µg/ml) and chloramphenicol (1µg/ml)) as appropriate) to OD<sub>550</sub> = 0.1. The flasks were then incubated at 20°C on a reciprocating shaker until the growth reached OD<sub>550</sub> = 0.5. The cultures were then induced by adding IPTG (0.5mM for LARd1(1275-1613) and 2mM for ZAP70(4-260)-6His) and the incubation continued, under the conditions described, for a further 24 hours. LARd1(1275-1613) and ZAP70(4-260)-6His accumulation was measured in the seeder cultures and IPTG induced cultures described above by scanning Coomassie blue stained SDS-PAGE gels of whole cell lysates of the sampled bacteria as is well known in the art. The results are summarised below in Table 9.

**Table 9**

HOST STRAIN	PLASMID	Accumulation level % TMP*	
		BASAL: (seeder culture)	INDUCED
LARd1(1275-1613)			
BL21(DE3)	pZen1911	18	40
BL21(DE3) pLysS	pZen1911	nd <sup>(1)</sup>	13
ZAP70(4-260)-6His			
MSD460(DE3)	pZen1914	0.4	12
MSD460(DE3) pLysS	pZen1914	nd <sup>(1)</sup>	nd <sup>(1)</sup>

\*TMP: Total microbial protein

1. not detected on Coomassie blue stained SDS-PAGE gels

This example further exemplifies the poor performance of pET11a in terms of high basal expression. Reducing basal expression in the absence of inducer using pLysS reduces the level of basal expression but adversely influences induced productivity.

20

### **Example 7**

*E.coli* strain BL21(DE3) was transformed separately with plasmids pZen1977 (pET11a:MCP-1(9-76)) and pZen1848 (pZT7#3.3:MCP-1(9-76)) expressing MCP-1(9-76). The resultant recombinant strains were purified and maintained in glycerol stocks at -80°C. An aliquot of each culture was removed from stock and streaked separately on to L-agar plates

(supplemented with ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate to maintain selection) to separate single colonies after growth for 16 hours at 37°C . A single colony of each culture was then inoculated into each of two 250ml Erlenmeyer flasks containing 75ml of L-broth (+ 1g/L glucose and ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate). The flasks were incubated at 37°C on a reciprocating shaker for 16 hours. Each of these cultures was then used to inoculate three 250ml Erlenmeyer flasks containing 75ml L-broth (1g/L glucose and ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate) to OD<sub>550</sub> = 0.1. The flasks were then incubated at 37°C, 30°C and 20°C on a reciprocating shaker until the growth reached OD<sub>550</sub> = 0.5. The cultures were then induced by adding IPTG (0.25mM final) and the incubation continued, under the conditions described, for a further 5- 24 hours. MCP-1(9-76) accumulation was measured by scanning Coomassie blue stained SDS-PAGE gels of whole cell lysates of the sampled bacteria as is well known in the art. Partitioning (solubility) of MCP-1(9-76) in the cytoplasmic (soluble) and pellet (insoluble) fractions of cells was determined by subjecting sampled bacteria to sonication lysis as is well known in the art. The results are summarised below in Table 10.

**Table 10**

VECTOR	Temperature °C	Induction time (h)	Accumulation MCP-1(9-76) % TMP*	Solubility %
pET11a: MCP-1(9-76)	20	24	7	100
pET11a: MCP-1(9-76)	30	24	3	100
pET11a: MCP-1(9-76)	37	5	4	100
pZT7#3.3: MCP-1(9-76)	20	24	12	100
pZT7#3.3: MCP-1(9-76)	30	24	14	95
pZT7#3.3: MCP-1(9-76)	37	5	22	80

\*TMP = Total microbial protein

20

The utility of vector pZT7#3.3 for high level soluble accumulation of MCP-1(9-76) is clearly evident from the data presented above.

**Example 8**

*E. coli* strain MSD460(DE3) was transformed separately with plasmids pZen1914 (pET11a:ZAP70(4-260)-6His) and pZen1913 (pZT7#3.3:ZAP70(4-260)-6His) expressing ZAP70(4-260)-6His. The resultant recombinant strains were purified and maintained in glycerol stocks at -80°C. An aliquot of each culture was removed from stock and streaked separately on to L-agar plates (supplemented with ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate to maintain selection) to separate single colonies after growth for 16 hours at 37°C. A single colony of each culture was then inoculated into each of two 250ml Erlenmeyer flasks containing 75ml of L-broth (+ 1g/L glucose and ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate). The flasks were incubated at 30°C on a reciprocating shaker for 16 hours. Each of these cultures was then used to inoculate a 250ml Erlenmeyer flask containing 75ml L-broth (1g/L glucose and ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate) to OD<sub>550</sub> = 0.1. The flasks were then incubated at 20°C on a reciprocating shaker until the growth reached OD<sub>550</sub> = 0.5. The cultures were then induced by adding IPTG (2mM (final)) and the incubation continued, under the conditions described, for a further 24 hours.

ZAP70(4-260)-6His accumulation after induction was measured by scanning Coomassie blue stained SDS-PAGE gels of whole cell lysates of the sampled bacteria as is well known in the art. Partitioning (solubility) of ZAP70(4-260)-6His in the cytoplasmic (soluble) and pellet (insoluble) fractions of cells was determined by subjecting sampled bacteria to sonication lysis as is well known in the art. The sonication lysis buffer included protease inhibitors (1mM phenylmethylsulphonyl flouride (PMSF), 1mM benzamidine and 1mM iodoacetamide) to reduce proteolytic degradation of ZAP70(4-260)-6His during sample processing. The results are summarised below in Table 11.

25 **Table 11**

VECTOR	ZAP70(4-260)-6His Accumulation % TMP*	Solubility %
pET11a: ZAP70(4-260)-6His	11	<5
pZT7#3.3: ZAP70(4-260)-6His	11	70

\*TMP = Total microbial protein

The utility of vector pZT7#3.3 for the soluble accumulation of ZAP70(4-260)-6His is clearly exemplified by the data in the table above.

## 5 Example 9

*E.coli* strain MSD624(DE3) was transformed separately with plasmids pZen1953 (pET11a:CPB [D253K]-6His-cmyc) and pZen1954 (pZT7#3.3:CPB[D253K]-6His-cmyc) expressing CPB[D253K]-6His-cmyc. The resultant recombinant strains were purified and maintained in glycerol stocks at -80°C. An aliquot of each culture was removed from stock and  
10 streaked separately on to L-agar plates (supplemented with ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate to maintain selection) to separate single colonies after growth for 16 hours at 37°C. A single colony of each culture was then inoculated into each of two 250ml Erlenmeyer flasks containing 75ml of L-broth (+ 1g/L glucose and ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate). The flasks were incubated at 37°C on a reciprocating  
15 shaker for 16 hours. Each of these cultures was then used to inoculate ten 2L Erlenmeyer flasks containing 600ml L-broth (1g/L glucose and ampicillin (50µg/ml) or tetracycline (10µg/ml) as appropriate) to OD<sub>550</sub> = 0.1. The flasks were then incubated at 20°C on a reciprocating shaker until the growth reached OD<sub>550</sub> = 0.5. The cultures were then induced by adding IPTG (0.001, 0.0025, 0.005, 0.0075, 0.01, 0.025, 0.05, 0.075, 0.1 and 0.25mM IPTG (final)) and the incubation  
20 continued, under the conditions described, for a further 48 hours. The cells were then harvested (4°C, 25000 x g, 20 minutes) and subjected to osmotic shock cell fractionation (as is well known in the art) to isolate the cellular fraction containing proteins partitioned in the soluble *E.coli* periplasmic fraction. The accumulation of biologically active CPB[D253K]-6His-cmyc in the soluble *E.coli* periplasmic extract was determined by measuring the release of hippuric acid from  
25 the substrate hippuryl-L-glutamine as follows.

Cell free periplasmic extract (125µl) was added to a test tube containing 100µl 25mM Tris buffer (pH 7.5), 2.5µl 100mM zinc chloride and 0.5mM substrate (hippuryl-L-glutamine). This was incubated at 37°C for 24 hours. The reaction was stopped by adding 250µl "Stop solution" (40%  
30 methanol (HPLC grade), 60% 50mM phosphate buffer (Sigma P8165), 0.2% w/v trichloroacetic acid. After mixing any precipitate formed was removed by centrifugation (4°C, 16000 x g, 3 minutes). The amount of hippuric acid in the cleared supernatant was then determined using HPLC as is well established in the art.

The accumulation of biologically active CPB[D253K]-6His-cmyc was determined by reference to a standard curve prepared with purified active recombinant CPB[D253K]-6His-cmyc and hippuric acid (Sigma H6375).

The accumulation in the periplasm of *E.coli* of biologically active CPB[D253K]-6His-5 cmyc ( as  $\mu\text{g}$  active material/L of culture) is presented in Figure 15.

### **Example 10**

*E.coli* strain MSD624(DE3) was transformed separately with plasmids pZen1999 (pET11a:A5B7(Fab')<sub>2</sub>) and pZen1997 (pZT7#3.3: A5B7(Fab')<sub>2</sub>) expressing A5B7(Fab')<sub>2</sub>. The resultant recombinant strains were purified and maintained in glycerol stocks at -80°C. An aliquot of each culture was removed from stock and streaked separately on to L-agar plates (supplemented with ampicillin (50 $\mu\text{g}/\text{ml}$ ) or tetracycline (10 $\mu\text{g}/\text{ml}$ ) as appropriate to maintain selection) to separate single colonies after growth for 16 hours at 37°C. A single colony of each culture was then inoculated into each of two 250ml Erlenmeyer flasks containing 75ml of L-broth (+ 1g/L glucose and ampicillin (50 $\mu\text{g}/\text{ml}$ ) or tetracycline (10 $\mu\text{g}/\text{ml}$ ) as appropriate). The flasks were incubated at 37°C on a reciprocating shaker for 16 hours. Each of these cultures was then used to inoculate thirteen 2L Erlenmeyer flasks containing 600ml L-broth (1g/L glucose and ampicillin (50 $\mu\text{g}/\text{ml}$ ) or tetracycline (10 $\mu\text{g}/\text{ml}$ ) as appropriate) to OD<sub>550</sub> = 0.1. The flasks were then incubated at 20°C on a reciprocating shaker until the growth reached OD<sub>550</sub> = 0.5. The cultures were then induced by adding IPTG (0.005, 0.01, 0.025, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2 and 0.25mM IPTG (final)) and the incubation continued, under the conditions described, for a further 48 hours. The cells were then harvested (4°C, 25000 x g, 20 minutes) and subjected to osmotic shock cell fractionation (as is well known in the art) to isolate the cellular fraction containing proteins partitioned in the soluble *E.coli* periplasmic fraction. The accumulation of biologically active A5B7(Fab')<sub>2</sub>/A5B7(Fab') in the soluble *E.coli* periplasmic extract was estimated by determining the binding of A5B7(Fab')<sub>2</sub>/A5B7(Fab') to human tumour carcinoembryonic antigen (CEA) in an ELISA assay. The accumulation in the periplasm of *E.coli* of biologically active A5B7(Fab')<sub>2</sub>/A5B7(Fab') ( as mg active material/L of culture) is presented in Figure 16.

30

With both proteins (described in Examples 9 and 10 above), pZT7#3.3 accumulates higher levels of active product in the periplasm of *E.coli* than pET11a. The data presented in Figures 15-16 clearly demonstrates how the modulation characteristics of pZT7#3.3 can be exploited to



optimise recombinant protein yields. These examples exemplify the use of pZT7#3.3 vector for secretion. However, it will be readily apparent to those skilled in the art how the basal level of expression/modulation of expression characteristics of pZT7#3.3 also facilitates the expression and accumulation of heterologous membrane proteins.

5

**Table 12**

PCR primer #1 (lac I 5'-3')

10 GATGCTATAATGCATGACACCATCGAATGGCGCAA

PCR primer #2 (lacI 3'-5')

CAGTATGCACAGTATGCATTTACATTAATTGCGTTGCGCTC

15

5'-3' oligomer #3

AATTCcagaCATATGGTACCAGTACTctatACTAGTtgaaGGATCCatgcCTCGAGaacgCTGCA  
GagctAAGCTTgacaAGATCTaa

20

3'-5' oligomer #4

gatcttAGATCTtgtcAAGCTTtagctCTGCAGcggttCTCGAGgcatGGATCCttcaACTAGT  
atagAGTACTGGTACCATATGtctgG

25

5'-3' oligomer #5

agcttAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTA  
GCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGa

30

3'-5' oligomer #6

gatctCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCAAGGGGTATGCTAGTTATTG  
CTCAGCGGTGGCAGCAGCCAACCTCAGCTTCCTTTCGGGCTTTGTTa

5

5'-3' oligomer #7

tcgagGCATTGTCCTCTTAGTTAAATGGATATAACGAGCCCCCTCCTAAGGGCTAATTGCA  
GGTTCGATTTCCTGCAGGGGACTCCActgca

10

3'-5' oligomer #8

gTGGAGTCCCCTGCAGGAATCGAACCTGCAATTAGCCCTTAGGAGGGGCTCGTTATAT  
CCATTAACTAAGAGGACAATGCc

15

5'-3' oligomer #9

cctATTATATTACTAATTAATTGGGGACCCTAGAGGTCCCCTTTTTTATTTTAAAAccatgg  
aaccaaccg

20

3'-5' oligomer #10

aattcggttggttccatgTTTTAAATAAAAAAGGGGACCTCTAGGGTCCCCAATTAATTAGTA  
ATATAATagg

25

5'-3' oligomer #11

aattcCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCT  
AGAAATAATTTTGTTTAACTTTAAGAAGGAGATATAca

30

3'-5' oligomer #12

tatgTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGGAATTGTTATCCGC  
TCACAATTCCCCTATAGTGAGTCGTATTAATTTCGg

5

5'-3' oligomer #13

aattcCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGCTCACAATTCCCCTCTA  
GAAATAATTTTGTTTAACTTTAAGAAGGAGATATAca

10

3'-5' oligomer #14

tatgTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGGAATTGTGAGCGCT  
CACAATTCCCCTATAGTGAGTCGTATTAATTTCGg

15

5'-3' oligomer #15

catggACTGGTTAACAACCAACCGGAATTGTGAGCGGATAACAATTCCTCCAAGAACAA  
CCATCCTAGCAACACGGCGGTCCCCg

20

3'-5' oligomer #16

aattcGGGGACCGCCGTGTTGCTAGGATGGTTGTTCTTGGAGGAATTGTTATCCGCTCAC  
AATTCCGGTTGGTTGTTAACACGTc

25

5'-3' oligomer #17

catggACGTGTTAACAACCAACCGGAATTGTGAGCGCTCACAATTCATCCAAGAACAA  
CCATCCTAGCAACACGGCGGTCCCCg

30

3'-5' oligomer #18

aattcGGGGACCGCCGTGTTGCTAGGATGGTTGTTCTTGGATGGAATTGTGAGCGCTCAC  
AATTCCGGTTGGTTGTTAACACGTC

**TABLE 13****hTNF $\alpha$  sequence**

Nde I  
CATATGGTACGTAGCTCCTCTCGCACTCCGTCGATAAGCCGGTTGCTCAT  
GTATACCATGCATCGAGGAGAGCGTGAGGCAGGCTATTCGGCCAACGAGTA  
GTAGTTGCTAACCCTCAGGCAGAAGGTCAGCTGCAGTGGCTGAACCGTC  
CATCAACGATTGGGAGTCCGTCTTCCAGTCGACGTCACCGACTTGGCAG  
GCGCTAACGCCCTGCTGGCAAACGGCGTTGAGCTCCGTGATAACGAGTCG  
CGCGATTGCGGGACGACCGTTTGCCGCAACTCGAGGCACTATTGGTCGAGC  
TGGTACCTTCTGAAGGTCTGTACCTGATCTATTCTCAAGTACTGTTCAA  
ACCATGGAAGACTTCCAGACATGGACTAGATAAGAGTTCATGACAAGTT  
GGGTCAGGGCTGCCCGTCGACTCATGTTCTGCTGACTCACACCATCAGCCG  
CCAGTCCCGACGGGCAGCTGAGTACAAGACGACTGAGTGTGGTAGTCGGC  
TATTGCTGTATCTTACCAGACCAAAGTTAACCTGCTGAGCGCTATCAAG  
ATAACGACATAGAATGGTCTGGTTTCAATTGGACGACTCGCGATAGTTC  
TCTCCGTGCCAGCGTGAAACTCCCGAGGGTGCAGAAGCGAAACCATGGTAT  
AGAGGCACGGTCGCACTTTGAGGGCTCCACGCTTCGCTTTGGTACCATA  
GAACCGATCTACCTGGGTGGCGTATTTCAACTGGAGAAAGGTGACCGTC  
CTTGGCTAGATGGACCCACCGCATAAAGTTGACCTCTTTCCACTGGCAG  
TGTCCGCAGAAATCAACCGTCCTGACTATCTAGATTTGCTGAATCTGGCC  
ACAGGCGTCTTTAGTTGGCAGGACTGATAGATCTAAAGCGACTTAGACCGG  
BamH I  
AGGTGTACTTCGGTATTATCGCACTGTAATAATAAGGATCC  
TCCACATGAAGCCATAATAGCGTGACATTATTCTTAGG

**Table 14****ZAP70 (4-260) 6HIS sequence**

Nde I  
CATATGCCCGCGGCGCACCTGCCCTTCTTCTACGGCAGCATCTCGCGTGCCGAGGCCGAGGAGCACCTGAAGCTGGCGGG 80  
GTATACGGGCGCCGCGTGGACGGGAAGAAGATGCCGTCGTAGAGCGCACGGCTCCGGCTCCTCGTGGACTTCGACCGCCC

CATGGCGGACGGGCTCTTCTGCTGCGCCAGTGCCCTGCGCTCGTGCGGCGCTATGTGCTGTGCGCTCGTGACGATGTGC 16  
GTACCGCTGCCCCGAGAAGGACGACGCGGTACGGACGCGAGCGACCCGCCGATACGACAGCGAGCACGTGCTACACG

GCTTCCACCACTTTCCCATCGAGCGCCAGCTCAACGGCACCTACGCCATTGCCGGCGGCAAAGCGCACTGTGGACCGGCA 24  
CGAAGGTGGTGAAAGGGTAGCTCGCGGTCGAGTTGCCGTGGATGCGGTAACGGCCGCCGTTTCGCGTGACACCTGGCCGT

GAGCTCTGCGAGTTCTACTCGCGCGACCCCGACGGGCTGCCCTGCAACCTGCGCAAGCCGTGCAACCGCCGTCGGGCCCT 32  
CTCGAGACGCTCAAGATGAGCGCGCTGGGGCTGCCGACGGGACGTTGGACGCGTTCGGCACGTTGGCCGGCAGCCCGGA

CGAGCCGACGCCGGGGTCTTCGACTGCCTGCGAGACGCCATGGTGCGTGACTIONGCGCCAGACGTGGAAGCTGGAGG 40  
GCTCGGCGTCGGCCCCAGAAGCTGACGGACGCTCTCGGTAACACGCACTGATGCACGCGGTCTGCACCTTCGACCTCC

GCGAGGCCCTGGAGCAGGCCATCATCAGCCAGGCCCGCAGGTGGAGAAGCTCATTGCTACGACGGCCACGAGCGGATG 48  
CGCTCCGGGACCTCGTCCGGTAGTAGTCGGTCCGGGCGTCCACCTCTTCGAGTAACGATGCTGCCGGGTGCTCGCCTAC

CCCTGGTACCACAGCAGCCTGACGCGTGAGGAGGCCGAGCGCAAACCTTTACTCTGGGGCGCAGACCGACGGCAAGTTCT 56  
GGGACCATGGTGTCGTCGGACTGCGCACTCCTCCGGCTCGCGTTTGAATGAGACCCCGCGTCTGGCTGCCGTTCAAGGA

GCTGAGGCCGCGGAAGGAGCAGGGCACATACGCCCTGTCCCTCATCTATGGGAAGACGGTGTACCACTACCTCATCAGCC 64  
CGACTCCGGCGCCTTCTCGTCCCGTGTATGCGGGACAGGGAGTAGATACCCTTCTGCCACATGGTGTGGAGTAGTCGG

AAGACAAGGCGGGCAAGTACTGCATTCCCGAGGGCACCAAGTTTGACACGCTCTGGCAGCTGGTGGAGTATCTGAAGCTG 72  
TTCTGTTCCGCCCCTTCATGACGTAAGGGCTCCCGTGGTTCAAACCTGTGCGAGACCGTCGACCACCTCATAGACTTCGAC

AAGGCGGACGGGCTCATCTACTGCCTGAAGGAGGCCCTGCCCAACAGCAGTGCCAGCCATCACCATCACCATCACTAATA 80  
TTCCGCCTGCCCGAGTAGATGACGGACTTCCTCCGGACGGGGTTGTCGTACGGTCGGTAGTGGTAGTGATTAT

Bgl II  
AAGATCT  
→ 807  
TTCTAGA

**Table 15****LARd1 (aa1275-1623) sequence**

Nde I  
CATATGGTACCAACCCACTCTCCGTCCTAAGGATGAGCAGTCGATCGGACTGAAGGACTCCTTGCTGGCCCACTCCTCTGACCCCTGTG 90  
GTATACCATGGTTGGGTGAGAGGCAGGAGATTCTACTCGTCAGCTAGCCTGACTTCCTGAGGAACGACCAGGTTGAGGAGACTGGGACAC

GAGATGCGGAGGCTCAACTACCAGACCCAGGTATGCGAGACCACCCACCCATCCCCATACCGACCTGGCGGACAACATCGAGCGCCTC 18  
CTCTACGCCTCCGAGTTGATGGTCTGGGTCCATACGCTCTGGTGGGTGGGTAGGGGTAGTGGCTGGACCGCCTGTTGTAGCTCGCGGAG

AAAGCCAACGATGGCCTCAAGTTCTCCAGGAGTATGAGTCCATCGACCTGGACAGCAGTTCACGTGGGAGAATTCAAACCTGGAGGTG 27  
TTTCGGTTGCTACCGGAGTTCAAGAGGGTCTCATACTCAGGTAGCTGGGACCTGTCTCAAGTGCACCCCTCTTAAGTTTGACCTCCAC

AACAAGCCCAAGAACCGCTATGCGAATGTCATCGCTACGACCACTCTCGAGTCATCCTTACCTCTATCGATGGCGTCCCCGGGAGTGAC 36  
TTGTTGCGGTTCTTGCGGATACGCTTACAGTAGCGGATGCTGGTGAGAGCTCAGTAGGAATGGAGATAGCTACCGCAGGGGCCCTCACTG

TACATCAATGCCAACTACATCGATGGCTACCGCAAGCAGAATGCCTACATCGCCACGAGGGCCCCCTGCCCGAGACCATGGGCGATTTT 45  
ATGTAGTTACGGTTGATGTAGCTACCGATGGCGTTCTGCTTACGGATGTAGCGGTGCGTCCCGGGGACGGGCTCTGGTACCGCTAAAG

TGGAGAATGGTGTGGGAACAGCGCACGGCCACTGTGGTCATGATGACACGGCTGGAGGAGAAGTCCCGGGTAAATGTGATCAGTACTGG 54  
ACCTCTTACCACACCCCTTGTCGCGTGCCGGTGACACCACTACTACTGTGCCGACCTCCTCTTCAGGGCCCATTTTACACTAGTCATGACC

CCAGCCCGTGGCACCAGACCTGTGGCCTTATTCAGGTGACCCCTGTTGGACACAGTGGAGCTGGCCACATACACTGTGCGCACCTTCGCA 63  
GGTCGGGACCGTGGCTCTGGACACCGGAATAAGTCCACTGGGACAACCTGTGTCACTCGACCGGTGTATGTGACACGCGTGAAGCGT

CTCCACAAGAGTGGCTCCAGTGAGAAGCGTGAGCTGCGTCAGTTTCAGTTCATGGCCTGGCCAGACCATGGAGTTCTGAGTACCCAACT 72  
GAGGTGTTCTCACCGAGGTCACTCTTCGCACTCGACGCAGTCAAAGTCAAGTACCGGACCGGTCTGGTACCTCAAGGACTCATGGGTTGA

CCCATCCTGGCCTTCTACGACGGGTCAAGGCCTGCAACCCCTAGACGCAGGGCCCATGGTGGTGCCTGACGCGCGGGCGTGGGCCGC 81  
GGGTAGGACCGGAAGGATGCTGCCAGTTCGGGACGTTGGGGATCTGCGTCCCGGTACCAACACGTGACGTGCGGCCCGACCCGGCG

ACCGGCTGCTTCATCGTGATTGATGCCATGTTGGAGCGGATGAAGCACGAGAAGACGGTGGACATCTATGGCCACGTGACCTGCATGCCA 90  
TGGCCGACGAAGTAGCACTAACTACGGTACAACCTCGCCTACTTCGTGCTCTTCTGCCACCTGTAGATACCGGTGCACTGGACGTACGCT

TCACAGAGGAACATACATGGTGCAGACGGAGGACCAGTACGTGTTTCATCCATGAGGCGCTGCTGGAGGCTGCCACGTGCGGCCACACAGAG 99  
AGTGTCTCCTTGATGTACCACGTCTGCCTCCTGGTCATGCACAAGTAGGTACTCCGCGACGACCTCCGACGGTGACGCCGGTGTGTCTC

Bgl II  
GTGCCTGCCCCGAACCTGTATGCCCACTAATGAAGATCT 1029  
CACGGACGGGCGTTGGACATACGGGTGATTACTTCTAGA

**TABLE 16****Bovine pancreatic DNase 1 sequence**

Nde I  
 CATATGCTTAAGATCGCTGCTTTCAACATACGTACCTTCGGTGAATCTA  
 GTATACGAATTCTAGCGACGAAAGTTGTATGCATGGAAGCCACTTAGAT  
 AAATGTCTAACGCTACGCTAGCATCTTACATCGTACGCATCGTACGCCGTT  
 TTTACAGATTGCGATGCGATCGTAGAATGTAGCATGCGTAGCATGCGGCAA  
 ACGATATCGTTCTGATCCAGGAAGTTCGCGACTCTCACCTGGTTGCAGT  
 TGCTATAGCAAGACTAGGTCCTTCAAGCGCTGAGAGTGGACCAACGTCA  
 TGGTAAACTTCTAGACTACCTGAACCAGGACGACCCGAACACCTACCACTA  
 ACCATTTGAAGATCTGATGGACTTGGTCCTGCTGGGCTTGTGGATGGTGT  
 CGTTGTTTCTGAACCCCTCGGGCGTAACCTTTACAAAGAACGGTACCTG  
 GCAACAAAGACTTGGGGAGCCCGCATTGAGAATGTTTCTTGCCATGGAC  
 TTCCTGTTCCGTCCGAACAAAGTTTCAGTACTGGATACCTACCAGTACGAC  
 AAGGACAAGGCAGGCTTGTTTCAAAGTCATGACCTATGGATGGTCATGCTG  
 GACGGATGCGAATCTTGCGGTAACGACTCTTCTCCCGGGAACCGGCTG  
 CTGCCTACGCTTAGAACGCCATTGCTGAGAAAGAGGGCCCTTGGCCGAC  
 TTGTTAAATTCTCGAGCCACTCTACCAAGGTTAAAGAGTTCGCTATCGTTG  
 AACAATTTAAGAGCTCGGTGAGATGGTTCCAATTTCTCAAGCGATAGCAAC  
 CTCTGCACAGCGCGCGTCTGACGCTGTTGCTGAAATCAACTCTCTGTA  
 GAGACGTGTCGCGCGGAGACTGCGACAACGACTTTAGTTGAGAGACAT  
 CGACGTTTACCTGGACGTTTACGAGAAATGGCACCTGAACGACGTCATGCT  
 GCTGCAAATGGACCTGCAAGTCGCTTTACCGTGGACTTGCTGCAGTACGA  
 GATGGGTGACTTCAACGCTGACTGCTCTTATGTAACCTCTTCTCAGTGG  
 CTACCCACTGAAGTTGCGACTGACGAGAATACATTGGAGAAGAGTCACC  
 TCATCGATTGCTCTGCGCACCTCGTCGACCTTCCAGTGGCTGATCCCGGAC  
 AGTAGCTAAGCAGACGCGTGGAGCAGCTGGAAGGTCACCGACTAGGGCCTG  
 TCCGCTGACACCACCGCTACTAGTACCAACTGCGCTTACGACCGTATCG  
 AGGCGACTGTGGTGGCGATGATCATGGTTGACGCGAATGCTGGCATAGC  
 TTGTTGCTGGATCCCTGCTGCAGTCTTCTGTTGTACCGGGTAGCGCGGCCC  
 AACACGACCTAGGGACGACGTCAGAAGACAACATGGCCCATCGCGCCGGG  
 CGTTGACTTCCAGGCTGCGTATGGTCTTTGAAACGAAATGGCGCTGGCC  
 GCAAGCTGAAGGTCCGACGCATACCAGAAAGCTTGCTTTACCGCGACCGG  
 Bgl II  
 ATCTCTGATCACTACCCGGTTGAGGTTACCCTGACCTAATAGAGATCT  
 TAGAGACTAGTGATGGGCCAACTCCAATGGGACTGGATTATCTCTAGA 798

**Table 17****human carboxypeptidase B (mutant D253>K) 6His cmc sequence**

ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCCATGGCGGCAACTGGTCACTCTTACGAGAAG 90  
TACTTTATGGATAACGGATGCCGTGGCGACCTAACAAATAATGAGCGACGGTTGGTCCGTACCGCCGTTGACCAGTGAGAATGCTCTTC

TACAACAAGTGGGAAACGATAGAGGCTTGGACTCAACAAGTCGCCACTGAGAATCCAGCCCTCATCTCTCGCAGTGTATCGGAACCACA 18  
ATGTTGTTACCCCTTTGCTATCTCCGAACCTGAGTTGTTACAGCGTGACTCTTAGGTCGGGAGTAGAGAGCGTCACAATAGCCTTGGTGT

TTTGAGGGACGCGCTATTTACCTCCTGAAGGTTGGCAAAGCTGGACAAAATAAGCCTGCCATTTTCATGGACTGTGGTTCCATGCCAGA 27  
AAACTCCCTGCGCGATAAATGGAGGACTTCCAACCGTTTCGACCTGTTTTATTTCGGACGGTAAAAGTACCTGACACCAAAGGTACGGTCT

GAGTGGATTTCTCCTGCATTCTGCCAGTGGTTTGTAAAGAGAGGCTGTTTCGTACCTATGGACGTGAGATCCAAGTGACAGAGCTTCTCGAC 36  
CTCACCTAAAGAGGACGTAAGACGGTCACCAACATTCTCTCCGACAAGCATGGATACCTGCACCTAGGTTCACTGTCTCGAAGAGCTG

AAGTTAGACTTTTATGTCCTGCCTGTGCTCAATATTGATGGCTACATCTACACCTGGACCAAGAGCCGATTTTGGAGAAAGACTCGCTCC 45  
TTCAATCTGAAAATACAGGACGGACACGAGTTATACTACCGATGTAGATGTGGACCTGGTTCTCGGCTAAAACCTCTTCTGAGCGAGG

ACCCATACTGGATCTAGCTGCATTGGCACAGACCCCAACAGAAATTTTGATGCTGGTTGGTGTGAAATTGGAGCCTCTCGAAACCCCTGT 54  
TGGGTATGACCTAGATCGACGTAACCGTGTCTGGGGTTGTCTTTAAACTACGACCAACCACACTTTAACCTCGGAGAGCTTTGGGGACA

GATGAAACTTACTGTGGACCTGCCGACAGTCTGAAAAGGAGACCAAGGCCCTGGCTGATTTTCATCCGCAACAACTCTCTTCCATCAAG 63  
CTACTTTGAATGACACCTGGACGGCGTCTCAGACTTTTCTCTGGTTCCGGGACCGACTAAAGTAGGCGTTGTTTGAGAGAAGGTAGTTC

GCATATCTGACAATCCACTCGTACTCCCAATGATGATCTACCTTACTCATATGCTTACAACTCGGTGAGAACAAATGCTGAGTTGAAT 72  
CGTATAGACTGTTAGGTGAGCATGAGGGTTTACTACTAGATGGGAATGAGTATACGAATGTTTGAGCCACTCTTGTACGACTCAACTTA

GCCCTGGCTAAAGCTACTGTGAAAGAAGTTGCCTCACTGCACGGCACCAAGTACACATATGGCCCGGGAGCTACAACAATCTATCTGTCT 81  
CGGGACCGATTTGATGACACTTTCTTGAACGGAGTGACGTGCCGTGGTTTCATGTGTATACCGGGCCCTCGATGTTGTTAGATAGGACGA

GCTGGGGGCTCTAAAGACTGGGCTTATGACCAAGGAATCAGATATTCCTTCACCTTTGAACTTCGAGATACAGGCAGATATGGCTTTCTC 90  
CGACCCCCGAGATTTCTGACCCGAATACTGGTTCTTAGTCTATAAGGAAGTGAAACTTGAAGCTCTATGTCCGCTATACCGAAAGAG

CTTCCAGAATCCAGATCCGGGCTACCTGCGAGGAGACCTTCCTGGCAATCAAGTATGTTGCCAGCTACGTCTGGAACACCTGTACCAC 99  
GAAGGTCTTAGGGTCTAGGCCGATGGACGCTCCTCTGGAAGGACCGTTAGTTCATACAACGGTCGATGCAGGACCTTGTGGACATGGT

CACCATCACCACCATGAGTTTCGAGGAGCAGAAGCTGATCTCTGAGGAGGACCTGAACTAATAA 1053  
GTGGTAGTGGTGGTACTCAAGCTCCTCGTCTTCGACTAGAGACTCCTCCTGGACTTGATTATT



-31-

**Table 19****Human monocyte chemotactic protein MCP-1 (9-76) sequence**

ATGGTTACCTGCTGTTATAACTTCACCAACCGTAAATCTCAGTGCAGAGGCTCGCGAGCTATAGAAGAATCACCAGCAGCAAGTGTCCTC  
TACCAATGGACGACAATATTGAAGTGGTTGGCATTCTAGAGTCACGTCTCCGAGCGCTCGATATCTTCTTAGTGGTCGTCGTTACAGGG 90

AAAGAAGCTGTGATCTTCAAGACCATTGTGGCCAAGGAGATCTGTGCTGACCCCAAGCAGAAGTGGGTTTCAGGATTCCATGGACCACCTG  
TTTCTTCGACACTAGAAGTTCTGGTAACACCGGTTCTCTAGACACGACTGGGGTTCGTCTTACCCAAGTCCTAAGTACCTGGTGGAC 18

GACAAGCAAACCCAACTCCGAAGACTTGATGA  
CTGTTTCGTTTGGGTTTGAGGCTTCTGAACTACT 213

TABLE 20A5B7 F(ab')<sub>2</sub> sequences

CATATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCGATGG  
 GTATACTTTATGGATAACGGATGCCGTCGGCCACCTAACAATAATGAGCGACGGGTGGTCGCTACC  
 CCCAGGTGCAGCTGCAGGAATCTGGTGGTGGCTTAGTTCAACCTGGTGGTTCCTGAGACTCT  
 GGGTCCACGTCGACGTCCTTAGACCACCACCGAATCAAGTTGGACCACCAAGGGACTCTGAGA  
 CCTGTGCAACTTCTGGGTTCACTTCACTGATTACTACATGAACTGGGTCCGCCAGCCTCCAGGAAA  
 GGACACGTTGAAGACCCAAGTGAAGTGACTAATGATGTAATTGACCCAGGCGGTGGAGGTCTTT  
 GGCACCTGAGTGGTGGGTTTTATTGGAACAAAGCTAATGGTTACACAACAGAGTACAGTGC  
 CCGTGAACCTACCAACCCAAAATAACCTTTGTTTCGATTACCAATGTGTTGTCATGTACAG  
 ATCTGTGAAGGGTCGGTTCACCATCTCCAGAGATAAATCCCAAAGCATCTCTATCTTCAAATGAAC  
 TAGACACTTCCAGCCAAGTGGTAGAGGTCTCTATTTAGGGTTTCGTAGGAGATAGAAGTTACTTG  
 ACCCTGAGAGCTGAGGACAGTGCCACTTATTACTGTACAAGAGATAGGGGGCTACGGTCTAC  
 TGGGACTCTCGACTCCTGTACGGTGAATAATGACATGTTCTCTATCCCCGATGCCAAGATG  
 YTTGACTACTGGGGCCAAGGCACCACGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCCATCGGTCT  
 AAACGTATGACCCCGTTCCGTGGTGCCAGTGGCAGAGGAGTGGAGGTGGTTCCCGGGTAGCCAGA  
 TCCCCCTGGCACCTCTCCAAGAGCACCTCTGGGGGCACAGCGCCCTGGGCTGCCCTGGTCA  
 AGGGGGACCGTGGGAGGAGGTTCTCGTGGAGACCCCGTGTGCGCGGGACCCGACGGACCACT  
 AGGACTACTTCCCGAACCCTGACGGTGTCTGGAACTCAGCGCCCTGACCAAGCGGTGCACAC  
 TCCTGATGAAGGGCTTGGCCACTGCCACAGCACCTTGAGTCCGCGGGACTGGTCCGCGCACGTGTG  
 CTTCCCGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTC  
 GAAGGGCCGACAGGATGTGAGGAGTCTGAGATGAGGGAGTGTGCGCACCACTGACACGGGAG  
 CAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAACCCAGCAACCAAGGTGAC  
 GTCGTGCAACCCGTGGGTCTGGATGTAGACGTTGCACTTAGTGTGGGGTGGTGTGGTTCAGCTG  
 AAGAAAGTTGAGCCCAATCTGTGACAAGACGCACAGTGCCTCCCGCGTGGCCGGCTCCGGAA  
 TTCTTTCAACTCGGGTTAGAACACTGTTCTGCGTGTGACGGCGGCACGGGGCCAGGGCCTT  
 CTGCTGGGTGGCCCGTAATAGCTAGCGTTAACATGCAAATTCTATTTCAAGGAGACAGTCATAATGA  
 GACGACCCACCGGGCATTATCGATCGCAATTGTACGTTTAAGATAAAGTTCCTCTGTCACTATTACT  
 AATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCTGCCCAACCAGCGATGGCCG  
 TTATGGATAACGGATGCCGTGCGGACCTAACAATAATGAGCGACGGGTGGTTCGTACCGGC

Table 20 /continued over

TABLE 20A5B7 F(ab')<sub>2</sub> sequencesTable 20 /continued


ACATCGAGCTCTCCAGTCTCCAGCAATCCTGTCTGCATCTCCAGGGGAGAAGGTCACAATGACTTG  
TGTAGCTCGAGAGGGTCAGAGGTCGTTAGGACAGACGTAGAGGTCCCTCTTCCAGTGTTACTGAAC  
CAGGGCCAGCTCAAGTGTAACCTACATTCACTGGTACCAGCAGAAGCCAGGATCCTCCCCAA  
GTCCCGGTCGAGTTCACATTGAATGTAAGTGACCATGGTCGTCTTCGGTCCTAGGAGGGGTT  
ATCCTGGATTTATGCCACATCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCT  
TAGGACCTAAATACGGTGTAGGTGGACCGAAGACCTCAGGGACGAGCGAAGTCACCGTCACCCAGA  
GGGACCTCTTACTCTCTCACAATCAGCAGAGTGGAGGCTGAAGATGCTGCCACTTATTACTGC  
CCCTGGAGAATGAGAGAGTGTTAGTCGTCTCACCTCCGACTTCTACGACGGTGAATAATGACG  
CAACATTGGAGTAGTAAACCACCGACGTTCCGGTGGAGGCACCAAGCTCGAGATCAAACCGACTGTGG  
GTTGTAACCTCATCATTGTTGGTGGCTGCAAGCCACCTCCGTGGTTCGAGCTCTAGTTTGCTGACACC  
CTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACCTGCCTCTG  
GACGTGGTAGACAGAAAGTACAAGGCGGCTAGACTACTCGTCAACTTTAGACCTTGACGGAGAC  
TTGTGTGCCCTGCTGAATAACTTCTATCCAGAGAGGCCAAAGTACAGTGGGAAGGTGGATAACGCCCT  
AACACACGGACGACTTATTGAAGATAGGGTCTCTCCGGTTTCATGTCACCTTCCACCTATTGCGGGA  
CCAATCGGGTAACCTCCAGGACAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCT  
GGTTAGCCCATTGAGGGTCTCTCACAGTGTCTCGTCTGTCTGTTCCGTGCTGGATGTCCGA  
CAGCAGCACCTTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACC  
GTCGTGCTGGGACTGCGACTCGTTTCGTCTGATGCTCTTTGTGTTTCAGATGCGGACGCTTCAGTGG  
CATCAGGGCCTGAGTTCGCGCGTCACAAAGAGCTTCAACCGCGGAGAGTGTAGTAAGGATCC  
GTAGTCCCGGACTCAAGCGGGCAGTGTTCGGAAGTTGGCGCTCTCACAATCATTCCTAGG  
AGCTCGAATTCCATCGATGATATCAGATCT 1590  
TCGAGCTTAAGGTAGCTACTATAGTCTAGA

Claims:


1. A T7 based promoter-driven protein expression system comprising an operator sequence downstream of the T7 promoter sequence, and having a further operator  
5 sequence upstream of the T7 promoter sequence.
2. A protein expression system as claimed in claim 1 wherein the further operator sequence is a native lac operator (lacO) sequence.
- 10 3. A protein expression system as claimed in claim 1 wherein the further operator sequence is a perfect palindrome operator (ppop) sequence.
4. A protein expression system as claimed in claim 3 wherein the native operator sequence downstream of the T7 promoter sequence is replaced by a ppop sequence. so  
15 as to provide a tandem ppop operator.
5. A plasmid which comprises a target gene under T7 promoter control, and comprising an operator sequence downstream of the T7 promoter sequence, and having a further operator sequence upstream of the T7 promoter sequence.  
20
6. A plasmid as claimed in claim 5 wherein the further operator sequence is a native lac operator (lacO) sequence.
7. A plasmid as claimed in claim 5 wherein wherein the further operator  
25 sequence is a perfect palindrome operator (ppop) sequence.
8. A plasmid as claimed in claim 4 wherein the native operator sequence downstream of the T7 promoter sequence is replaced by a ppop sequence, so as to provide a tandem ppop operator.  
30

-35-


9. A plasmid selected from pZT7#3.0, pZT7#3.1, pZT7#3.2 and pZT7#3.3
10. The plasmid pZT7#3.3.
- 5 11. A host cell transformed by a plasmid as claimed in any one of claims 5-10
12. A host cell transformed by plasmid pZT7#3.3.
13. E. Coli transformed by pZT7#3.3.
- 10 14. A method of use of an expression system or host cells as claimed in any one of the previous claims in the production of recombinant protein.
15. Recombinant protein when produced by the method of claim 14.

**Figure 1**

2/16


**Figure 2**

3/16


**Figure 3**




4/16


**Figure 4**

**Figure 5**



**Figure 6**

7/16

**Figure 7**

8/16




**Figure 8**


Figure 9



**Figure 10**





**Figure 11**






12/16

**Figure 12**

**Figure 13** $Q_p$  (max): mg/g/h

14/16


**Figure 14**TNF accm (max)  
% TMP

15/16


**Figure 15**

Accumulation biologically active

CPB [D253K]-6His-cmyc: ug/L culture



16/16

**Figure 16**A5B7(Fab')<sub>2</sub>/A5B7(Fab'): mg/L culture

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02175

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N15/72 C12N1/21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DUBENDORFF J W ET AL: "CONTROLLING BASAL EXPRESSION IN AN INDUCIBLE T7 EXPRESSION SYSTEM BY BLOCKING THE TARGET T7 PROMOTER WITH LAC REPRESSOR" JOURNAL OF MOLECULAR BIOLOGY, vol. 219, no. 1, 1991, pages 45-59, XP000605448 see the whole document	15
A	---	1-14
A	NOVAGEN: "pET EXPRESSION SYSTEM INFORMATION PACKAGE" August 1995 XP002084177 see the whole document ---	1-14
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

Date of the actual completion of the international search

12 November 1998

Date of mailing of the international search report

24/11/1998

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02175

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP 0 502 637 A (ICI PLC) 9 September 1992  cited in the application  see page 2, line 40 - line 45  -----</p>	1-14

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02175

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0502637 A	09-09-1992	AU 659130 B	11-05-1995
		CA 2061721 A	27-08-1992
		FI 920835 A	27-08-1992
		GB 2253852 A,B	23-09-1992
		JP 5056790 A	09-03-1993
		NZ 241703 A	26-07-1994
<hr/>			